Humanized Monoclonal Antibody Conjugated To The Pro-drug Seco-duocarmycinhydroxyb
Humanized Monoclonal Antibody Conjugated To The Pro-drug Seco-duocarmycinhydroxyb Uses, Dosage, Side Effects, Food Interaction and all others data.
Humanized Monoclonal Antibody Conjugated To The Pro-drug Seco-duocarmycinhydroxyb is under investigation in clinical trial NCT03262935 (SYD985 vs. Physician's Choice in Participants With Her2-positive Locally Advanced or Metastatic Breast Cancer).
| Trade Name | Humanized Monoclonal Antibody Conjugated To The Pro-drug Seco-duocarmycinhydroxyb |
| Generic | Trastuzumab duocarmazine |
| Trastuzumab duocarmazine Other Names | Immunoglobulin g1-kappa, anti-(homo sapiens erbb2 (epidermal growth factor receptor 2, receptor tyrosineprotein kinase erbb-2, egfr2, her2, her-2, p185cerbb2, neu, cd340)), humanized monoclonal antibody conjugated to the pro-drug seco-duocarmycinhydroxyb, Trastuzumab duocarmazine |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here Humanized Monoclonal Antibody Conjugated To The Pro-drug Seco-duocarmycinhydroxyb
